Home > Insider Trading > Filing (0000902664-19-003156)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576263	Mirati Therapeutics Inc.	MRTX	Pharmaceutical Preparations (2834)	462693615

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1633313	Avoro Capital Advisors Llc	110 Greene Street Suite 800 New York NY 10012		No	No	Yes	No
1701815	Behzad Aghazadeh	C/O Avoro Capital Advisors Llc 110 Greene Street, Suite 800 New York NY 10012		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	Disposition	2019-07-23	62,500	$101.88	3,800,000	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.1321 to $104.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC (formerly venBio Select Advisor LLC), a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC (formerly venBio Select Fund LLC), a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.